Viking inks CordenPharma deal to boost obesity drug supply [Yahoo! Finance]
Viking Therapeutics, Inc. (VKTX)
Last viking therapeutics, inc. earnings: 4/30 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.vikingtherapeutics.com
Company Research
Source: Yahoo! Finance
Dive Brief: Viking Therapeutics is secure production capacity for its experimental obesity drug, announcing Tuesday it will prepay contract manufacturer CordenPharma $150 million to produce up to 200 million injectable and 1 billion oral doses of the treatment annually. The deal comes as Viking prepares to start late-stage testing of an injectable form of the therapy, VK2735, by the end of June. The company said in February it has enough drug supply to complete its Phase 3 program. The agreement could help Viking meet eventual demand for its weight loss drug, if approved, something even market leaders Novo Nordisk and Eli Lilly struggled with initially. Still, company shares fell in Tuesday morning trading, as “investors could view the deal as a negative development with respect to Viking's takeout prospects,” wrote William Blair analyst Andy Hsieh. Dive Insight: Like Eli Lilly's fast-selling obesity drug Zepbound, VK2735 stimulates two gut hormones called GLP-1 and GIP. Ph
Show less
Read more
Impact Snapshot
Event Time:
VKTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VKTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VKTX alerts
High impacting Viking Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
VKTX
News
- Viking Therapeutics, Inc. (NASDAQ: VKTX) was upgraded by analysts at Cantor Fitzgerald to a "strong-buy" rating.MarketBeat
- Viking Therapeutics, Inc. (NASDAQ: VKTX) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $104.00 price target on the stock.MarketBeat
- Why Viking Therapeutics Stock Popped Today [Yahoo! Finance]Yahoo! Finance
- Viking Therapeutics, Inc. (NASDAQ: VKTX) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $75.00 price target on the stock, down previously from $95.00.MarketBeat
- Viking Therapeutics, Inc. (NASDAQ: VKTX) had its price target lowered by analysts at Morgan Stanley from $105.00 to $102.00. They now have an "overweight" rating on the stock.MarketBeat
VKTX
Earnings
- 4/23/25 - Miss
VKTX
Sec Filings
- 4/24/25 - Form 10-Q
- 4/23/25 - Form DEFA14A
- 4/23/25 - Form DEFR14A
- VKTX's page on the SEC website